R&D Pipeline

Latest Competitive Analysis of Merck Sharp & Dohme Drug Pipeline

18 October 2023
2 min read

Merck's recent revenue performance remains steady, with the K drug continuing to grow and earning the title of "New Generation Drug King". Additionally, the HPV vaccine also continues to maintain its momentum. These two key products have managed to fill the gap left by the rapid shrinkage of Molnupiravir and the patent cliff of Sitagliptin. Despite a significant decline in profitability, the market value is still approaching $300 billion.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of Merck.

图形用户界面, 应用程序

描述已自动生成

A significant portion of ongoing research and development still centers around various expanded applications and combination plans for the K drug. 

Noteworthy recent advancements include Phase III clinical results for the adjuvant/neoadjuvant treatment of stage II/IIIA/IIIB NSCLC, and Phase 2B clinical results for the mRNA-4157 cancer vaccine developed in partnership with Moderna for treating melanoma. 

Cardiovascular pipeline developments include Phase III clinical data and NDA submission for the PAH drug Sotatercept, Phase 2A clinical results for the GLP-1/GCGR dual agonist Efinopegdutide in treating NAFLD, and Phase II clinical data for the oral PCSK9 drug MK-0616. Vaccine pipeline advancements include preliminary Phase III clinical results for the 21-valent pneumococcal vaccine V-116, and the acquisition of Prometheus to obtain the TL1A antibody.

图形用户界面, 文本

描述已自动生成

Avidity Biosciences presents encouraging results for AOC 1001, showing progress and long-term safety in multiple areas for Type 1 Myotonic Dystrophy patients
Latest Hotspot
4 min read
Avidity Biosciences presents encouraging results for AOC 1001, showing progress and long-term safety in multiple areas for Type 1 Myotonic Dystrophy patients
18 October 2023
Avidity Biosciences Reports Fresh Positive Results for AOC 1001, Showing Progress in Various Additional Functional Measures and Long-term Safety and Acceptability in Individuals with Type 1 Myotonic Dystrophy.
Read →
Reducing the Risk of FTO Missed Detection in Special Referential Sequences of Patents
Bio Sequence
2 min read
Reducing the Risk of FTO Missed Detection in Special Referential Sequences of Patents
18 October 2023
The patent and literature contain sequences of nucleic acids containing N and protein sequences containing X. I'm interested in reducing the risk of missing such sequences. Is there a recommended database where I can search for these sequences?
Read →
Unveiling the FTO Retrieval of Multi-gene Elements within the AAV Domain
Bio Sequence
2 min read
Unveiling the FTO Retrieval of Multi-gene Elements within the AAV Domain
18 October 2023
In the AAV field, common inventions involve the replacement and combination of expression-related gene regulatory elements.
Read →
The FDA has granted approval for TOFIDENCE™ (tocilizumab-bavi), a biosimilar of ACTEMRA®, created by Bio-Thera Solutions
Latest Hotspot
3 min read
The FDA has granted approval for TOFIDENCE™ (tocilizumab-bavi), a biosimilar of ACTEMRA®, created by Bio-Thera Solutions
18 October 2023
Bio-Thera Solutions has made it known that its associate company, Biogen, was recently notified by FDA about the approval of TOFIDENCE (tocilizumab-bavi) in an intravenous mixture.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.